HK1258252A1 - 腺嘌呤綴合物化合物及其作為疫苗佐劑的用途 - Google Patents

腺嘌呤綴合物化合物及其作為疫苗佐劑的用途

Info

Publication number
HK1258252A1
HK1258252A1 HK19100616.3A HK19100616A HK1258252A1 HK 1258252 A1 HK1258252 A1 HK 1258252A1 HK 19100616 A HK19100616 A HK 19100616A HK 1258252 A1 HK1258252 A1 HK 1258252A1
Authority
HK
Hong Kong
Prior art keywords
vaccine adjuvants
conjugate compounds
adenine
adenine conjugate
compounds
Prior art date
Application number
HK19100616.3A
Other languages
English (en)
Inventor
Hitoshi Ban
Yukihiro Nishio
Padma Malyala
Bilikallahalli K Muralidhara
Marcus Wong
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Astrazeneca Ab filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of HK1258252A1 publication Critical patent/HK1258252A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK19100616.3A 2015-09-29 2019-01-15 腺嘌呤綴合物化合物及其作為疫苗佐劑的用途 HK1258252A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562234481P 2015-09-29 2015-09-29
PCT/JP2016/004375 WO2017056494A1 (en) 2015-09-29 2016-09-28 Adenine conjugate compounds and their use as vaccine adjuvants

Publications (1)

Publication Number Publication Date
HK1258252A1 true HK1258252A1 (zh) 2019-11-08

Family

ID=57138095

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100616.3A HK1258252A1 (zh) 2015-09-29 2019-01-15 腺嘌呤綴合物化合物及其作為疫苗佐劑的用途

Country Status (9)

Country Link
US (1) US10597397B2 (zh)
EP (1) EP3355933B1 (zh)
JP (1) JP6764930B2 (zh)
CN (1) CN108348618B (zh)
CA (1) CA2998995A1 (zh)
DK (1) DK3355933T3 (zh)
ES (1) ES2805724T3 (zh)
HK (1) HK1258252A1 (zh)
WO (1) WO2017056494A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3355933B1 (en) * 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
JP7545955B2 (ja) * 2019-03-04 2024-09-05 国立感染症研究所長 インフルエンザhaスプリットワクチンの製造方法
JPWO2020204173A1 (zh) * 2019-04-05 2020-10-08
WO2024020684A1 (en) * 2022-07-26 2024-02-01 Zymeworks Bc Inc. Immunomodulator purine-derived compounds, conjugates thereof, and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
AU732361B2 (en) 1997-11-28 2001-04-26 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compounds
ATE404561T1 (de) 2001-04-17 2008-08-15 Dainippon Sumitomo Pharma Co Neue adeninderivate
WO2005001022A2 (en) 2003-04-10 2005-01-06 3M Innovative Properties Company Methods and compositions for enhancing immune response
PL1653959T3 (pl) 2003-08-14 2015-10-30 3M Innovative Properties Co Modyfikatory odpowiedzi immunologicznej modyfikowane lipidami
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
WO2008115319A2 (en) * 2007-02-07 2008-09-25 Regents Of The University Of California Conjugates of synthetic tlr agonists and uses therefor
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
BRPI0919937A2 (pt) 2008-10-24 2016-02-16 Glaxosmithkline Biolog Sa composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina
CA2752074A1 (en) 2009-02-11 2010-08-19 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
TR201909600T4 (tr) 2009-08-07 2019-07-22 Glaxosmithkline Biologicals Sa Lipide edilmiş oksoadenin türevleri.
US20130202629A1 (en) * 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
WO2012011606A1 (en) 2010-07-20 2012-01-26 Dainippon Sumitomo Pharma Co., Ltd. Process for preparing adenine compounds and intermediates thereof
HUE033901T2 (en) 2010-08-17 2018-01-29 3M Innovative Properties Co Formulations and formulations for lipidized immune response modifying compounds and related processes
FR2968662B1 (fr) * 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
EP3355933B1 (en) * 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants

Also Published As

Publication number Publication date
EP3355933B1 (en) 2020-05-06
CA2998995A1 (en) 2017-04-06
CN108348618B (zh) 2021-06-15
US10597397B2 (en) 2020-03-24
JP2018529717A (ja) 2018-10-11
ES2805724T3 (es) 2021-02-15
EP3355933A1 (en) 2018-08-08
JP6764930B2 (ja) 2020-10-07
US20180282334A1 (en) 2018-10-04
DK3355933T3 (da) 2020-07-20
WO2017056494A1 (en) 2017-04-06
CN108348618A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
ZA201801035B (en) Vaccine compositions
ZA201904717B (en) Therapeutic hpv18 vaccines
PL3148576T3 (pl) Kompozycja szczepionki przeciwko zakażeniu streptococcus suis
ZA201708713B (en) Multivalent pneumococcal conjugate vaccine
GB201518684D0 (en) Vaccine
HK1258252A1 (zh) 腺嘌呤綴合物化合物及其作為疫苗佐劑的用途
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
IL251120A0 (en) Immunogenic/therapeutic glycoside preparations and their uses
IL248223A0 (en) Compositions of vaccine
GB201801566D0 (en) Methods and compositions for nanormulsion vaccine formulations
IL264605A (en) A multivalent vaccine
GB201522132D0 (en) Vaccine
GB201616904D0 (en) Vaccine
GB201703529D0 (en) Vaccine composition
HRP20182167T1 (hr) Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba
GB201712904D0 (en) Vaccine
GB201704126D0 (en) Vaccine
GB201703809D0 (en) Vaccine
GB201611084D0 (en) Vaccine compositions
GB201603029D0 (en) Vaccine
GB201521608D0 (en) Vaccine composition
GB201501153D0 (en) Immunogenic formulations
GB201405857D0 (en) Immunogenic formulations